The Landing Research Institute was formerly the Cardiovascular Research Laboratory of Harvard Medical School. In 2000, the team of scientists from the laboratory was introduced into China as a whole, and established the nation's * "Academic Special Zone" — the Institute of Molecular Medicine of Nanjing University. By the end of 2007, the Institute of Molecular Medicine had published more than 60 SCI papers, undertaken 30 national, provincial and ministerial-level scientific research projects, and received multiple awards including the Second Prize of the National Natural Science Award. In 2007, the team established the Biopharmaceutical Engineering Research Center of Nanjing University, settled in Suzhou, and actively applied for the "Engineering Center for Protein and Peptide Drugs of the Ministry of Education", and successfully passed the acceptance inspection. In the ten years from 2007 to 2016, the "Center" applied for 13 Chinese invention patents, published nearly 30 SCI papers, and completed the druggability research and technology transfer of multiple new drugs.
In 2017, based on long-term development, the team integrated resources and merged with the scientific research strength of Suzhou Landing Biopharmaceutical Co., Ltd. to establish the Landing Research Institute. The Landing Research Institute currently has an R&D team of more than 80 people led by several senior scientists who have studied and worked in the United States for many years. It will adhere to the purpose of "innovation-driven development", continue to focus on researching diseases that seriously threaten human health such as cardiovascular diseases and metabolic diseases, and develop a batch of globally pioneering novel antibody and peptide drugs. At the same time, our E. coli antibody production technology and ton-scale protein and peptide production technology are also in a * position.
We are well aware that talent is the driving force for career development. The Landing Research Institute will continue to vigorously introduce and cultivate talent and expand the high-level R&D team in the biopharmaceutical field. According to the people-oriented mechanism, we will build an environment conducive to the growth of innovative talent and provide a good development platform for their innovation and entrepreneurship. We have currently built a drug R&D and production base of more than 10,000 square meters. We will welcome the joining of outstanding talents from all walks of life with a * comfortable working environment, advanced facilities and equipment, and * competitive welfare benefits. Let us together leave our mark in the history of the development of human pharmaceutical and health undertakings!
What does Suzhou Landing Biopharmaceutical Co., Ltd. require? Who is Suzhou Landing Biopharmaceutical Co., Ltd. hiring? recruitment: 销售类占比最多占35.1%,其次是工厂生产类占26.7%. What education can get in at ? 大专占比最多占50.4%,其次是本科占38.2%. High education required at ? 硕士占4.6%. Work experience required at ? 1-3年占比最多占42%,其次是3-5年占33.6%. Where are the job locations at ? 苏州占比最多占56.5%,其次是上海占9.9%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows